Severe Sepsis Clinical Trial
Official title:
Therapeutic Effect of Sodium Selenite on Oxidative Stress in Patients With Severe Sepsis
This study looked at parenteral administration of selenium to septic patients and subsequently monitored dynamic changes of selected activities of antioxidant enzymes and the development of clinical status.
Patients will be divided into two groups. Se-group who received selenium supplementation
during hospitalization in the form of sodium selenite pentahydrate at 750 mg/day for 6 days
immediately after admission to our department (1000 mg of sodium selenite pentahydrate = 333
micrograms of selenium) (Selenase, Vivax; selenium hereinafter).
The placebo group will receive continuous saline NaCl 50 ml/day for 6 days as a continuous
infusion (excluding additional infusion therapy). Patients will be further divided into
subgroups according to OI on the day of admission to ICU. The oxygenation index (OI)
PaO2/FiO2 (partial pressure of oxygen in arterial blood/ fraction of inspired oxygen) ratio
in patients will be calculated daily.
The determination of biochemical and hematological parameters of blood samples will be as a
part of the routine diagnostic methods. Data collection for the Se-AOX study will be
performed at two-day intervals: T1 (1st-2nd day), T2 (3rd-4th day) and T3 (5th-6th day).
Kinetic methods for estimating the activities of glutathione peroxidase (GPx, E.C.
1.11.1.9), glutathione reductase (GR, E.C.1.6.4.2) will be performed using a kit
(Sigma-Aldrich, Germany) and that of superoxide dismutase (SOD, E.C. 1.15.1.1) by means of
the SOD-Assay Kit-WST (Fluka, Japan) following the user manual provided.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04804306 -
Sepsis Post Market Clinical Utility Simple Endpoint Study - HUMC
|
||
| Completed |
NCT04227652 -
Control of Fever in Septic Patients
|
N/A | |
| Recruiting |
NCT04005001 -
Machine Learning Sepsis Alert Notification Using Clinical Data
|
Phase 2 | |
| Recruiting |
NCT02899143 -
Short-course Antimicrobial Therapy in Sepsis
|
Phase 2 | |
| Completed |
NCT02539147 -
Characterization of Non-canonical Way in Inflammasome Monocytes of Patients With Severe Sepsis
|
N/A | |
| Completed |
NCT01929772 -
German Lactat Clearance in Severe Sepsis
|
N/A | |
| Completed |
NCT01932814 -
Acute Kidney Injury in Septic Critically Ill Patients : Are Aminoglycosides Really Harmful?
|
N/A | |
| Completed |
NCT01449721 -
Preemptive Resuscitation for Eradication of Septic Shock
|
N/A | |
| Active, not recruiting |
NCT01162109 -
Zinc Therapy in Critical Illness
|
Phase 1 | |
| Not yet recruiting |
NCT01211899 -
4G/5G Polymorphism of Plasminogen Activator Inhibitor-1 Gene and Disseminated Intravascular Coagulation in Severe Sepsis and Septic Shock
|
N/A | |
| Completed |
NCT00934011 -
Use of Inflammatory Biomarkers to Guide Antibiotic Therapy in Patients With Severe Infections
|
N/A | |
| Recruiting |
NCT00335907 -
Protocol-driven Hemodynamic Support for Patients With Septic Shock
|
N/A | |
| Completed |
NCT00463645 -
Investigation of Correlation Between Interstitial and Arterial Blood Glucose Concentrations in Septic Patients
|
N/A | |
| Completed |
NCT02361528 -
GM-CSF to Decrease ICU Acquired Infections
|
Phase 3 | |
| Completed |
NCT02734550 -
(1,3)-β-D-glucan Based Diagnosis of Invasive Candida Infection in Sepsis
|
N/A | |
| Completed |
NCT02973243 -
The Vital Signs to Identify, Target, and Assess Level (VITAL) Care Study III
|
N/A | |
| Terminated |
NCT03895853 -
Early Metabolic Resuscitation for Septic Shock
|
Phase 2 | |
| Completed |
NCT01945983 -
Early Use of Norepinephrine in Septic Shock Resuscitation
|
N/A | |
| Completed |
NCT01598831 -
Phase 3 Safety and Efficacy Study of ART-123 in Subjects With Severe Sepsis and Coagulopathy
|
Phase 3 | |
| Enrolling by invitation |
NCT02258984 -
Can the Venus 1000 Help Clinicians Treat Patients With Severe Sepsis or Acute Heart Failure? The CVP Trial
|
N/A |